To Assess the Pharmacokinetics of AZD1656 and its Metabolite in Type 2 Diabetes Mellitus Patients

Exclusion Criteria

• - Clinically significant progression of current disease or clinically relevant trauma, as judged by the Investigator, within 2 weeks before the first administration of the IP
• - Clinically significant neuropathy according to the Investigator. However subjects with diabetic neuropathy which is not clinically significant according to the Investigator may be included.